SCHEDULE: Anson Funds Discloses 4.9% Stake in Sellas Life Sciences
Beneficial Ownership Report
Anson Funds Management LP and related entities have disclosed a 4.9% beneficial ownership stake in Sellas Life Sciences Group, Inc. common stock.
Summary
- Anson Funds Management LP, Anson Management GP LLC, Mr. Tony Moore, Anson Advisors Inc., Mr. Amin Nathoo, and Mr. Moez Kassam collectively beneficially own 5,225,948 shares of Sellas Life Sciences Group, Inc. Common Stock.
- This ownership represents 4.9% of the outstanding shares of Common Stock.
- The calculation of the percentage is based on 99,777,487 shares issued and outstanding as of May 13, 2025, plus 4,950,948 shares receivable upon exercise of warrants.
- The reporting persons hold warrants that include a beneficial ownership limitation, preventing exercise if it would result in ownership exceeding 4.99% of the outstanding Common Stock.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of beneficial ownership, indicating a passive investment below the 5% threshold, and does not inherently convey positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
The filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future operations or financial performance.
Industry Context
This filing is a standard disclosure of an institutional investor's passive stake in a publicly traded company within the life sciences sector. It does not provide specific insights into broader industry trends or competitive dynamics beyond the ownership structure of Sellas Life Sciences.
Stakeholder Impact
- Shareholders: The disclosure of a significant, albeit passive, stake by an institutional investor like Anson Funds provides transparency regarding the company's ownership structure.
Key Dates
| Date | Description |
|---|---|
| 2025-05-13 | Date of Issuer's Quarterly Report on Form 10-Q, reporting 99,777,487 shares of Common Stock issued and outstanding. |
| 2025-06-30 | Date of event which requires filing of this statement. |
| 2025-08-14 | Date of filing of this Schedule 13G Amendment No. 1. |
Keywords
Sellas Life Sciences, Anson Funds, Beneficial Ownership, SEC Filing, Common Stock, Investment, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.